


Affordability Options for ZYMFENTRA

Once your doctor has prescribed ZYMFENTRA and enrolled you in Celltrion CONNECT[®], a dedicated case manager will talk you through your coverage and help identify affordability options.

If you have commercial health insurance

- ✓ Eligible patients with commercial insurance may pay as little as **\$0** per month for ZYMFENTRA through the Celltrion CARES[®] Co-pay Assistance Program*
- ✓ View complete program rules and apply online at **CelltrionCares.com**. Program maximums apply

*While patients must have commercial insurance to be eligible for the co-pay program, Celltrion CONNECT may provide additional information to patients about financial assistance options regardless of insurance type.



If you have commercial insurance and experience a delay in coverage due to an insurance denial

- ✓ The START program may provide ZYMFENTRA at no cost to you while your provider supports the appeal process for your medication
- ✓ Your provider must prescribe ZYMFENTRA for an FDA-approved indication and provide evidence of appeal activity for you to be eligible to stay in the program
- ✓ If eligible, you will receive a monthly shipment of ZYMFENTRA at your home while case managers work with your provider's office to support your appeal
- ✓ Other program terms and conditions apply[†]

You must have been enrolled in Celltrion CONNECT (with proof of valid commercial insurance) to be evaluated for this program.

- ✓ The BRIDGE program may provide ZYMFENTRA at no cost to you for up to 2 months if you experience a loss in coverage due to a job loss or life event, where you may need temporary support until your new (commercial) insurance takes effect
- ✓ Other program terms and conditions apply[†]

If you are uninsured and have exhausted all options for financial assistance

- ✓ You may be eligible to receive ZYMFENTRA at no cost as part of the Celltrion CONNECT Patient Assistance Program
- ✓ Patient Assistance Program eligibility criteria, terms, and conditions apply[†]

FDA, U.S. Food & Drug Administration.

*Please see full terms and conditions for Celltrion CARES at <https://www.celltrionconnect.com/zymfentra/co-pay-assistance>.

[†]Celltrion may provide ZYMFENTRA to eligible patients, including those with commercial insurance experiencing delays or a gap in coverage of ZYMFENTRA. Eligible patients must have been prescribed ZYMFENTRA for an FDA-approved indication, and their participation is in no way contingent on any requirement or obligation to purchase ZYMFENTRA or any other Celltrion product or service at any time. Patients who are covered, in whole or in part, through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs, or Department of Defense, are not eligible. Eligibility for continued participation will be verified periodically, and patients will not be eligible to continue participating if they no longer satisfy the eligibility criteria, including when initiation of coverage for ZYMFENTRA is approved by the patient's commercial insurance plan. This offering will end December 31, 2025. Void where prohibited or restricted by law, and Celltrion reserves the right to rescind, revoke, or amend the terms and conditions at any time without notice.

[†]Please see full terms and conditions for Celltrion PAP Program at <https://www.celltrionconnect.com/patient/zymfentra/patient-assistance-program>.

